NCT07521618Not yet recruiting
One-stop Diagnosis and Treatment for Suspected Lung Cancer: Combined RBS, nClE, OBCT and Ablation
An Exploratory Clinical Trial on the Integration of Detection, Sampling and Treatment of Peripheral Lung Cancer by Robotic Bronchoscopy System
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
Using RBS as the navigation and treatment platform, precisely navigate to the target lesion. Utilize r-EUBS and nCLE to identify the lesion, and when the confocal AI model recognizes the lesion as malignant, perform a biopsy. Subsequently, under the guidance of OBCT, carry out ablation treatment of the lesion.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 31 Mar 2026
- Start date
- 1 Apr 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Guangzhou Medical University
- Diseases
- Lung cancer
- NCT number
- NCT07521618
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 1 Apr 2026 to the primary completion date, 31 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Target lesion received radiotherapy within the past 6 months.
Other illness
- Severe pulmonary impairment (maximal voluntary ventilation \<40%).
- Poor general condition: widespread metastasis, severe infection, high fever, infectious/radiation inflammation around the lesion, obvious cachexia, severe organ dysfunction, severe anemia, uncorrectable metabolic/nutritional disorders.
- Active hepatitis B, active hepatitis C, known HIV-1/2 antibody positivity, or other active infections judged by the investigator to interfere with treatment.
- History of epilepsy, psychosis, or cognitive impairment.
- Other conditions deemed inappropriate by the investigator.
Lab values
- Severe bleeding tendency or irreversible coagulopathy (PT \>18 s, PTA \<40%).Platelet count \<70×10⁹/L; anticoagulant/antiplatelet therapy discontinued \<1 week before ablation (except prophylactic low-molecular-weight heparin).
Other
- Diffuse bilateral lung lesions unresponsive to ablation.
- Contraindication to bronchoscopy or inability to tolerate/cooperate with bronchoscopy.
- Other metastatic tumors with widespread metastasis; life expectancy \<3 months.
- Eastern Cooperative Oncology Group (ECOG) performance status \>2.
- Pregnant/lactating females; males or females planning conception during the trial.
Who the study is looking for
- Age ≥18 years, male or female.
- High-risk pulmonary nodule/tumor maximum diameter ≤3 cm.
- Lesion judged suitable for bronchial navigation-guided diagnosis and treatment.
- Ineligible for surgery or refuses surgery/radiotherapy; agrees to primary ablation therapy; provides written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.